Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 2

Status

Unknown 4Completed 2

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 3Other solid neoplasm 1Breast 1

Conditions

Neoplasms 3Solid Tumors 1Breast Neoplasms 1Advanced Cancer 1

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × indibulin × Clear all
NCT01113970 2013-01-30

Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer

Alaunos Therapeutics

Phase 1/2 Unknown
60 enrolled
Breast

Breast Neoplasms

NCT00591136 2012-07-19

Phase I Study of Indibulin in Patients With Solid Tumors

Alaunos Therapeutics

Phase 1 Completed
47 enrolled
Other solid neoplasm

Solid Tumors

NCT00591292 2012-07-19

Phase I Study in Advanced Solid Tumors

Alaunos Therapeutics

Phase 1 Unknown
22 enrolled
Tumor-Agnostic

Neoplasms

NCT00591383 2012-07-19

Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors

Alaunos Therapeutics

Phase 1 Unknown
10 enrolled
Tumor-Agnostic

Neoplasms

NCT00591890 2012-07-19

Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) Scans

Alaunos Therapeutics

Phase 1 Completed
20 enrolled

Advanced Cancer

NCT00726687 2012-07-19

Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors

Alaunos Therapeutics

Phase 1/2 Unknown
7 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡